Biomerica (NASDAQ:BMRA) Stock Crosses Below 200 Day Moving Average of $0.97

Biomerica, Inc. (NASDAQ:BMRAGet Free Report) crossed below its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $0.97 and traded as low as $0.70. Biomerica shares last traded at $0.72, with a volume of 59,331 shares traded.

Biomerica Stock Performance

The stock has a market capitalization of $12.19 million, a P/E ratio of -1.96 and a beta of -1.04. The stock has a 50-day moving average price of $0.98 and a two-hundred day moving average price of $0.97.

Biomerica (NASDAQ:BMRAGet Free Report) last released its quarterly earnings results on Friday, April 12th. The company reported ($0.11) earnings per share for the quarter. Biomerica had a negative net margin of 117.46% and a negative return on equity of 64.00%. The company had revenue of $1.02 million during the quarter.

Hedge Funds Weigh In On Biomerica

An institutional investor recently raised its position in Biomerica stock. Russell Investments Group Ltd. lifted its position in Biomerica, Inc. (NASDAQ:BMRAFree Report) by 15.0% in the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 201,563 shares of the company’s stock after acquiring an additional 26,288 shares during the period. Russell Investments Group Ltd. owned 1.20% of Biomerica worth $252,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 22.28% of the company’s stock.

About Biomerica

(Get Free Report)

Biomerica, Inc, a biomedical technology company, develops, patents, manufactures, and markets diagnostic and therapeutic products for the detection and/or treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, nasal or fecal specimens from patients in the diagnosis of various diseases, food intolerances, and other medical complications; or to measure bacteria, hormones, antibodies, antigens, or other substances which may exist in the human body, stools, or blood in extremely small concentrations.

Read More

Receive News & Ratings for Biomerica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biomerica and related companies with's FREE daily email newsletter.